Physician profile
Aobo Du
NPI 1619405248
$10,541.88
in general payments reported to CMS, 2019-2025
29 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $397 · 2021: $462 · 2022: $3,183 · 2023: $3,888 · 2024: $753 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,230 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,230.26 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,926.29 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,646.31 | 2022-2025 | Airsupra, Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $1,005.62 | 2022-2023 | Shingrix, Arexvy, Pediarix |
| Lilly USA, LLC | $834.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $830.05 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $700.54 | 2020-2024 | Xarelto, Spravato, Invega Sustenna |
| Bayer Healthcare Pharmaceuticals INC. | $585.62 | 2022-2024 | |
| Amgen INC. | $561.93 | 2021-2023 | Evenity, Prolia, Repatha |
| Amarin Pharma, INC. | $300.57 | 2019-2021 | |
| Madrigal Pharmaceuticals | $284.18 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $262.94 | 2020-2025 | Camzyos |
| Grifols USA, LLC | $241.61 | 2021-2023 | Prolastin-C Liquid |
| Biogen, INC. | $216.65 | 2021 | |
| Idorsia Pharmaceuticals US INC | $175.81 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $146.45 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.14 | 2022-2024 | |
| Gilead Sciences, INC. | $124.96 | 2019 | |
| Genzyme Corporation | $122.26 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $118.69 | 2023 | Opsumit, Uptravi |
| Exact Sciences Corporation | $90.51 | 2025 | The Cologuard Plus Collection Kit |
| Angiodynamics, INC. | $45.96 | 2025 | Smart Port Ct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.77 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $31.58 | 2022 | |
| Organon LLC | $31.13 | 2023 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $27.24 | 2022-2023 | |
| Scpharmaceuticals INC. | $23.34 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.23 | 2022 | |
| Merck Sharp & Dohme LLC | $12.81 | 2021 | |
| Abbott Laboratories | $12.79 | 2023 | Freestyle Libre 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aobo Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.